evidence: In this large US-based retrospective cohort study with nearly 25 000 remdesivir-exposed hospitalized patients identified between May 1, 2020, and May 3, 2021, remdesivir treatment was associated with an overall significantly reduced inpatient mortality among patients hospitalized with COVID-19 compared with PS-matched control patients. Our findings support the results of the ACTT-1 trial, which noted numerically lower inpatient mortality by day 29 in the remdesivir-treated group, a result that was not statistically significant as the trial was not powered for this secondary outcome (HR, 0.73 [95% CI, 0.52-1.03]).9 Similar inpatient mortality results were noted among hospitalized adults receiving remdesivir vs the local standard of care in the World Health Organization Solidarity open-label trial, which observed a statistically significant 13% reduction in the mortality rate among patients in the subgroup who required oxygen but not mechanical ventilation.11 These results among inpatients are bolstered by recent RCT findings noting that outpatient use of remdesivir was associated with an 87% reduction in the risk of hospitalization for COVID-19 among high-risk patients.7